Reports
In 2025, CTA supported an increasing workload that helped ensure Australia ranks #3 in the world for total number of Phase 1 clinical trials, with our Members proactively selected for the world’s best early phase studies. A record-breaking 2,000+ Australian patients were enrolled across CTA supported studies, with a large proportion of this recruitment taking place at regional Member sites, reinforcing the network’s shared commitment to improving equitable access to clinical trials.
This year, our report incorporates visual elements drawn from ‘For Those Who Wait’, a commissioned artwork by Aboriginal and Torres Strait Islander artist Safina Stewart. For Those Who Wait is featured in full on page 21, where Safina’s beautiful words articulate how First Nations cultural symbolism was woven through her artwork to reflect Cancer Trials Australia’s purpose and values.
After substantial membership growth over the previous year our membership remained stable in 2024, maintaining strong representation across all major Australian states and New Zealand, importantly with more than 30% of our Members situated in rural or regional locations.
Showcasing trends in Victorian cancer clinical trial participation from 2022-24, this dashboard is supported by the Victorian Government through the Department of Health and aggregates data provided by 19 Victorian research sites.
Building upon work undertaken for many years by Cancer Council Victoria (CCV) to collect and report on Victorian cancer clinical trials participation, this report represents a significant development within our growing sector, towards the capacity for deeper analysis of annual trends in cancer clinical trials and the participants who benefit.